New implantable cardiac monitor with three-lead ECG and active noise detection
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu klinická studie, časopisecké články, multicentrická studie
PubMed
27796409
DOI
10.1007/s00059-016-4492-7
PII: 10.1007/s00059-016-4492-7
Knihovny.cz E-zdroje
- Klíčová slova
- Artifacts, Atrial fibrillation, Cardiac arrhythmia, Electrocardiography, Predictive value,
- MeSH
- algoritmy MeSH
- design vybavení MeSH
- dospělí MeSH
- elektrokardiografie ambulantní přístrojové vybavení MeSH
- elektrokardiografie přístrojové vybavení MeSH
- fibrilace síní diagnóza chirurgie MeSH
- katetrizační ablace MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- pooperační komplikace diagnóza MeSH
- prospektivní studie MeSH
- protézy a implantáty * normy MeSH
- srdeční arytmie diagnóza chirurgie MeSH
- technologie dálkového snímání přístrojové vybavení MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinická studie MeSH
- multicentrická studie MeSH
BACKGROUND: A new implantable cardiac monitor (BioMonitor, Biotronik) with a continuous remote monitoring option was prospectively implanted in patients with suspected arrhythmias or for therapy control after atrial fibrillation (AF) ablation. A three-lead ECG detection was intended to make the implantation more independent of the implantation site and the electrical heart axis. Because noise is a frequent problem in implantable cardiac monitors, an active noise detection algorithm was implemented. The aim of the trial was to evaluate the clinical performance of the device. METHODS: The device performance was evaluated in a prospective nonrandomized multicenter study with a follow-up of 12 months. Study endpoints were device-related serious adverse events at 3 months, appropriate QRS detection in direct comparison with synchronized Holter ECG recordings, sensitivity and positive predictive value of arrhythmia detection in comparison with Holter ECG and independent of it, and noise burden during the entire follow-up period. RESULTS: The implantation was successful in all 152 patients. Two device-related serious adverse events (pocket infections) occurred by 3 months. The mean QRS amplitude of 0.3 ± 0.2 mV at implantation remained stable over 12 months. QRS sensing performance indicated little over- and undersensing in most patients. More than 80 % of the patients had more than 22 h of noise-free monitoring per day. CONCLUSION: BioMonitor effectively detects patients with bradycardia, tachycardia, AF, or asystole. Active noise detection seems to reduce the transmission of meaningless data without diminishing the positive predictive value of the device.
Department of Cardiology Charité University Hospital Berlin Germany
Department of Cardiology University Hospital Greifswald Germany
Department of Heart Failure and Devices Albertinen Hospital Hamburg Germany
Evangelical Hospital Bielefeld Germany
Evangelical Hospital Hubertus Berlin Germany
Faculty of Health and Social Sciences University of South Bohemia České Budejovice Czech Republic
Zobrazit více v PubMed
Europace. 2009 May;11(5):671-87 PubMed
Pacing Clin Electrophysiol. 2010 Sep;33(9):1149-52 PubMed
J Am Coll Cardiol. 2011 Jan 11;57(2):160-6 PubMed
Europace. 2016 Jul;18(7):1000-5 PubMed
Clinical evaluation of a small implantable cardiac monitor with a long sensing vector
